



Purpose

Indomethacin has been described as “practically insoluble in water” [1]; solubilities between 2-7 µg/mL have been reported [2,3]. However a higher value of 410 µg/mL has also been proposed [4]. Uncertainty undermines computational efforts to predict solubility [5]. Which value is correct?

Methods

The solubility of indomethacin was measured by two automated pH-metric titration methods. Firstly, a suspension of indomethacin in DI water was prepared at low pH and titrated with KOH solution. The data were compared with a Bjerrum curve calculated using intrinsic solubility, pK_a, sample concentration and pH. This curve depicts the disappearance of solid as it dissolves with increasing pH. Secondly, indomethacin was dissolved in ionized form at high pH and titrated with HCl until precipitation was detected. Thereafter, aliquots of KOH or HCl were added to maintain the system close to equilibrium, and the solubility was calculated from rates of pH change vs. concentration using mass and charge balance relationships.

Results

Solubility measured pH-metrically in experiments starting at low pH with original solid present was in the region of 4.0 µg/mL. Several attempts to measure solubility pH-metrically starting at pH 12 with re-precipitated sample present gave results of 400-500 µg/mL. It was then found that indomethacin decomposes at pH 12. Subsequent experiments starting at pH 9 gave results of 80 µg/mL. During some of these experiments, a sudden drop in solubility to around 10 µg/mL took place after several minutes at 80 µg/mL. It is suggested that these three measured solubilities (80, 10, 4 µg/mL) may represent the amorphous form and two crystalline forms.

Conclusion

Indomethacin can exist in forms with solubility between 80 and 10 µg/mL. However, the solubility of the most stable form appears to be in the region of 1 - 4 µg/mL.

References


1. O'Neil, M. J. The Merck Index, 13th Edition; Merck & Co., Inc.: Whitehouse Station, NJ, 2001.
2. Bergström, C. A. S.; Strafford, M.; Lazorova, L.; Avdeef, A.; Luthman, K.; Artursson, P., 2003. J Med Chem, 46, 558.
3. Nokhodchi, A. Javadzadeh, Y.; Siahi-Shadbad, M. R.; Barzegar-Jalali, M., 2005. J. Pharm. Pharmaceut. Sci. 8, 18.
4. Linäs, A. Glen, R. C.; Goodman, J. M., 2008. J. Chem. Inf. Model. 48, 1289.
5. Hewitt, M. Cronin, M. T.; Enoch, S. J.; Madden, J. C.; Roberts, D. W.; Dearden, J. C., 2009. J. Chem. Inf. Model. 49, 2572.
6. This work
7. Curry, S. H.; Brown, E. A.; Kuck, H.; Cassin, S., Can J Physiol Pharmacol 1982, 60 (7), 988-92.
8. Fini, A.; Fazio, G.; Feroci, G., Int. J. Pharm. 1995, 126, 95-102.
9. Aubrey-Medendorp, C.; Swadley, M. J.; Li, T., Pharm Res 2008, 25 (4), 953-9.
10. Hancock, B. C.; Parks, M., Pharm Res 2000, 17 (4), 397-404.
11. Yalkowsky, S.H. Dannenfelser, R.M. Aquasol Database of Aqueous Solubility, Coll. Pharm., U. Arizona, Tuscon AZ, 1998
12. Avdeef, A., Current Topics in Medicinal Chemistry 2001, 1, 277-351.
13. Method for determining solubility of a chemical compound. Stuart, M. Box, K. (2010) United States Patent 7723119.
14. Box, K.; Comer, J. E.; Gravestock, T.; Stuart, M., Chem Biodivers 2009, 6 (11), 1767-88.
15. Box, K. J.; Comer, J. E., Curr Drug Metab 2008, 9 (9), 869-78.
16. Box, K. J.; Völgyi, G.; Baka, E.; Stuart, M.; Takács-Novák, K.; Comer, J. E., J Pharm Sci 2006, 95 (6), 1298-307.
17. Stuart, M.; Box, K., Anal Chem 2005, 77 (4), 983-90.



Solubility experiments # 6 – 9 in Table 1 were done using SiriusTS3.

Some facts about indomethacin

Indomethacin is a non-steroidal anti-inflammatory drug. It is a carboxylic acid; the pK_a in 0.06 M ionic strength at 25°C is 4.13 [6]. It decomposes rapidly at high pH [7] to form p-chlorobenzoic acid and 5-methoxy-2-methyl-3-indoleacetic acid. It is reported to form aggregates in high ionic strength solutions and to form a poorly-soluble sodium salt [8]. It is known to form polymorphs; two of them, the α and γ forms, have been structurally solved. It can also form solvates, and its amorphous properties have been extensively studied [9]. Experimental aqueous solubility vs. time profiles for amorphous and crystalline indomethacin have been published [10], showing that the amorphous form was more soluble.



Measurements of indomethacin solubility

We measured the intrinsic solubility* of indomethacin by shake-flask at pH 1.42, and by potentiometric methods. Experiments # 6 - 9 were run under conditions chosen to avoid pitfalls listed above. They were run in low ionic strength conditions (to avoid salt formation). Titrations starting at high pH were not exposed to conditions above pH 9 (to avoid decomposition), and they were run in the presence of 50 µL of DMSO with 5 minutes of sonication at pH 9 (to aid dissolution).

Experiment #	Assay	Assay design	SOLUBILITY		Number of assays	Form switch observed?
			Kinetic	Intrinsic		
			µg/mL	µg/mL		
RESULTS FROM LITERATURE						
1	Yalkowsky [11]	Shake-flask?		0.94		
2	Avdeef [12]	pSOL. Determined using a cosolvent and extrapolation to 0% (w/w) cosolvent.		2.0		
3	Bergström [2]	pSOL. Determined using a cosolvent and extrapolation to 0% (w/w) cosolvent.		2.26		
4	Nokhodchi [3]	Shake-flask, at pH 1.2. 48 hour shaking, filtration, conc. by UV		3.88		
RESULTS MEASURED IN THIS WORK						
5	Shake flask	200 mg in 20mL of 0.05M HCl, pH 1.42. 24 hr. shaking, 24 hr. sedimentation, conc. by UV.		4.01	1	
6	Curve fitting	pH2 ↗ up. 3.8mg in 1.5 mL DI water. Original solid present at start, dissolved during experiment.		3.31	1	
7	CheqSol	pH9 ↘ down. 2 ± 0.3mg in 1.5mL DI water + 50µL DMSO, adj. to pH9, 5 min sonication to dissolve sample	77.3 ± 10.1	9.4 ± 1.6	3	Yes
8	Curve fitting	pH9 ↘ down. 2 ± 0.3mg in 1.5mL DI water + 50µL DMSO, adj. to pH9, 5 min sonication to dissolve sample	68.7 ± 5.4	79.8 ± 5.8	3	
9	Curve fitting	pH9 ↘ down. 2 ± 0.3mg in 1.5mL DI water + 50µL DMSO, adj. to pH9, 5 min sonication to dissolve sample	72.1	13.2	1	Yes
10	CheqSol	pH12 ↘ down. 12.7mg in 10mL 0.15 M KCl.		417	1	
		Results in purple represent the intrinsic solubility of the most stable crystalline form of indomethacin				
		Results in pale green probably represent the solubility of a more soluble crystalline form				
		Results in bright green probably represent the solubility of the amorphous form				
		Results in orange represent the solubility of a mixture of indomethacin and decomposition products				


Table 1. Measurements of indomethacin solubility

* Intrinsic solubility is the equilibrium solubility of the unionized form of the molecule. For indomethacin, an acid with pK_a of 4.2, this is equivalent to the solubility at low pH, e.g. below 2.2.

The intrinsic solubility of indomethacin


Jon Mole¹, Karl Box², John Comer², Sam Judge²

¹ Sirius Analytical Inc, Beverly, MA, USA ² Sirius Analytical Ltd, Forest Row, East Sussex, UK



Solubility of 410 µg/mL?

Linàs *et al* [4] published carefully measured values for the intrinsic solubility of 100 drugs, and invited readers to use them to train software to predict solubility of 32 measured but unpublished values. One of the unpublished values was indomethacin, 410 µg/mL. Difficulty was reported to predict this value [5]. It turns out that 410 µg/mL is incorrect, as explained here.



Sirius - Instrumentation and CRO Services for Physicochemical Profiling
www.sirius-analytical.com

Instrumentation

pK_a, logP & logD,
Solubility & dissolution
Surface Activity Profiling
Phospholipidosis

CRO Services

PhysChem properties – pK_a, logP, logD, solubility,
supersaturation, dissolution
Biorelevant media studies – FaSSIF/FeSSIF, excipients
Solid state assays – XRPD, DSC, TGA, Raman
Surface Tension – CMC, TSA, K_{AW}

For more information please contact
sirius@sirius-analytical.com

Sirius Analytical Ltd.
Riverside, Forest Row Business Park
Forest Row, West Sussex, RH18 5DW
Phone: +44 1342 820720 **Fax:** +44 1342 820725
Web: www.sirius-analytical.com